Source: Simply Better Brands.
  • Simply Better Brands’ (SBBC) PureKana brand has been recognized by the Brightfield Group as one of the fastest growing brands in the emerging CBD category
  • Brightfield Group is a leading research firm for emerging categories including CBD, cannabis, and wellness
  • PureKana is adding 15,000 new customers per month driving year-to-date growth of 366 per cent
  • Simply Better Brands (SBBC) is an omni-channel platform with diverse assets in the emerging plant-based and holistic wellness consumer product categories
  • Simply Better Brands Corp. (SBBC) opened trading at C$0.74

Simply Better Brands’ (SBBC) PureKana brand has been recognized by the Brightfield Group as one of the fastest growing brands in the CBD category.

Brightfield Group is a leading research firm for emerging categories including CBD, cannabis, and wellness.

Simply Better Brands CEO, Kathy Casey, commented on the news.

“In the roughly $5B CBD category of over 3,000 brands, our Q1 2022 performance places us with the Top 10 brand performers. Consumers are rewarding us for consumer-centric active ingredient wellness innovation in the need states of anxiety, pain, sleep, immunity, energy, and recreation. Our growth priority remains to relentlessly acquire customers by driving customer, category, channel and geographic expansion.”

The company’s CBD subsidiary brand, PureKana, has added approximately 15,000 new customers per month, driving year-to-date growth of 366 per cent.

Simply Better Brands (SBBC) is an omni-channel platform with diverse assets in the emerging plant-based and holistic wellness consumer product categories.

Simply Better Brands Corp. (SBBC) opened trading at C$0.74.

More From The Market Online

Manulife details steep rise in obesity and addiction treatment

Manulife (TSX:MFC) releases its Employee Health Report, shedding light on rising obesity and substance abuse treatment in Canada's workforce.

Buzz on the Bullboards: Volatility persists in the face of economic indicators

Canada’s main stock index struggled and the NASDAQ hit a high, demonstrating a continued appetite for tech stocks amidst market volatility.

Numinus approved for pioneering MDMA-based clinical trial

Numinus Wellness (TSX:NUMI) receives Health Canada approval for a clinical trial examining group models in MDMA-assisted psychotherapy.

Voyageur Pharmaceuticals signs $2.6M contract in Latin America

Voyageur Pharmaceuticals (TSXV:VM) announces its first international distribution agreement with a C$2.6 million commitment.